EZH2 and hepatocellular carcinoma: Knockdown or pharmacological inhibition of HDAC8 increased the infiltration of CD8+ T cells and enhanced the therapeutic effect of PD-L1 blockade for HCC.132 Zhang et al. found that combined treatment of DNMT and EZH2 inhibitors inhibited proliferation of human HCC cells and upregulated antitumor immune response.